3 Stocks Dragging In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 25 points (-0.1%) at 17,365 as of Monday, Nov. 3, 2014, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,608 issues advancing vs. 1,366 declining with 174 unchanged.

The Drugs industry currently sits down 0.2% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include Novo Nordisk A/S ( NVO), down 2.4%, Sanofi ( SNY), down 1.4%, Novartis ( NVS), down 1.4% and AstraZeneca ( AZN), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Shire ( SHPG) is one of the companies pushing the Drugs industry lower today. As of noon trading, Shire is down $2.28 (-1.1%) to $197.52 on light volume. Thus far, 471,706 shares of Shire exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $196.16-$198.77 after having opened the day at $198.64 as compared to the previous trading day's close of $199.80.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. Shire has a market cap of $39.2 billion and is part of the health care sector. Shares are up 41.4% year-to-date as of the close of trading on Friday. Currently there are 8 analysts that rate Shire a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Shire Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Amgen ( AMGN) is down $1.98 (-1.2%) to $160.20 on average volume. Thus far, 2.0 million shares of Amgen exchanged hands as compared to its average daily volume of 3.7 million shares. The stock has ranged in price between $160.02-$162.41 after having opened the day at $162.08 as compared to the previous trading day's close of $162.18.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $122.9 billion and is part of the health care sector. Shares are up 42.2% year-to-date as of the close of trading on Friday. Currently there are 7 analysts that rate Amgen a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $1.90 (-1.7%) to $110.10 on average volume. Thus far, 8.3 million shares of Gilead exchanged hands as compared to its average daily volume of 14.5 million shares. The stock has ranged in price between $108.81-$112.80 after having opened the day at $112.31 as compared to the previous trading day's close of $112.00.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $172.7 billion and is part of the health care sector. Shares are up 49.1% year-to-date as of the close of trading on Friday. Currently there are 14 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, solid stock price performance and impressive record of earnings per share growth. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Aluminum Prices Plummet as U.S. Is Open to Easing Sanctions on Russia's Rusal

Aluminum Prices Plummet as U.S. Is Open to Easing Sanctions on Russia's Rusal

Stocks Rise as Bond Yields Inch Closer to 3% Threshold

Stocks Rise as Bond Yields Inch Closer to 3% Threshold

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Trump to Blame for Oil's Recent Surge, Not OPEC

Trump to Blame for Oil's Recent Surge, Not OPEC

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday